TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33517477
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) discontinuation
Study: 33517701
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment on hospital admission (21.7%)
Study: 33517701
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of prior statin treatment
Study: 33518355
Drug: Ranolazine 375-750
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 375-750 mg (single-dose and multiple-dose)
Study: 33519339
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) transfusion (300 ml, 200-400 ml/treatment dose) at least once, up to 5 sessions, along with best standard of care.
Study: 33520317
Drug: Prolonged-release pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prolonged-release pirfenidone (PR-PFD) 1,200 mg/day
Study: 33520317
Drug: Prolonged-release pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prolonged-release pirfenidone (PR-PFD) 600 mg/day
Study: 33521534
Drug: Medical prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical prescriptions for fresh vegetables (21 servings/week for 10 weeks)
Study: 33522900
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of YKL-40 and MIP-1α in saliva
Study: 33523334
Drug: BI 836826
Normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 836826 in combination with gemcitabine and oxaliplatin
Study: 33524308
Drug: Uterine-sparing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine-sparing treatment
Study: 33524399
Drug: Leptin and
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin and gene signature for lymphocyte activation and dysregulated lipid metabolism
Study: 33524601
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg, day 1) and Anlotinib (12 mg, day 1-14) every 3 weeks
Study: 33526918
Drug: Prior lines
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior lines of systemic immunosuppressive therapy for cGVHD
Study: 33527351
Drug: Bayesian dose
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian dose regimen assessment method (DRtox)
Study: 33527447
Drug: Palatal (P)
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal (P) and Buccal (G) tissues
Study: 33527447
Drug: G and
Normalized name: Calcium Mag And Zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: G and P tissues
Study: 33528118
Drug: Recombinant subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant subunit herpes zoster vaccine (RZV); 2 doses given 2-6 months apart.
Study: 33528286
Drug: Single-agent selinexor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent selinexor
Study: 33529058
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously once every 3 weeks for ≤ 24 months
Study: 33529989
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg intravenously once every 3 weeks, 2 cycles prior to surgery)
Study: 33530933
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biomarkers with clinical risk factors
Study: 33531464
Drug: Estradiol challenge
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol challenge test (specific dosage and duration not provided)
Study: 33533507
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg QD on Days 1-5
Study: 33533507
Drug: GSK3640254 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 200 mg QD on Days 1-7
Study: 33533507
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg plus GSK3640254 200 mg QD on Days 1-7
Study: 33533986
Drug: Individualized management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized management of breakthrough cancer pain (BTcP) therapy
Study: 33534266
Drug: Specific COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific COVID-19 pharmacotherapy
Study: 33535013
Drug: Insulin suspension
Normalized name: Insulin Suspension Isophane (NPH) (Recombinant)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suspension during overnight basal up-titration
Study: 33535600
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibition as primary adjuvant therapy
Study: 33536021
Drug: Intravenous selexipag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous selexipag
Study: 33536130
Drug: Amisulpride treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride treatment for 4 weeks
Study: 33536430
Drug: MR-guided focused
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-guided focused ultrasound (MRgFUS) with intravenous microbubble administration
Study: 33536791
Drug: Multi-professional medication
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-professional medication reviews (MRs)
Study: 33536998
Drug: Bicycle simulator
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicycle simulator training, details on dosage and duration not available
Study: 33537232
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for four cycles.
Study: 33537232
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with FLOT regimen for four cycles.
Study: 33537232
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival (OS) and relapse-free survival (RFS) outcomes after treatment.
Study: 33537564
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose subcutaneous sterile water injection
Study: 33537564
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous saline injection
Study: 33538517
Drug: Immediate-release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbidopa/levodopa (IR)
Study: 33538517
Drug: Controlled-release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbidopa/levodopa (CR)
Study: 33538517
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in levodopa equivalent daily dose
Study: 33538517
Drug: Schwab and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwab and England Activities of Daily Living Scale
Study: 33538699
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health and self-management app (8-week program including Lung Attack Action Plan, education, medication overview, video consultation, and questionnaires)
Study: 33538761
Drug: Povidone Iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone Iodine Mouthwash, Gargle, and Nasal Spray
Study: 33539144
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Study: 33540481
Drug: Latency reversal
Normalized name: edrophonium chloride Injectable Solution [Reversol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latency reversal agents
Study: 33540485
Drug: DalcA (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DalcA (subcutaneous 150 IU/kg daily for 6 days)
Study: 33540485
Drug: DalcA (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DalcA (intravenous 75 IU/kg)
Study: 33540485
Drug: DalcA (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DalcA (subcutaneous 75 IU/kg)
Study: 33540485
Drug: DalcA (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DalcA (subcutaneous 150 IU/kg)
Study: 33540485
Drug: BeneFIX (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: BeneFIX (intravenous 75 IU/kg)
Study: 33541235
Drug: Home nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home nebulizer inhaled corticosteroid (ICS) therapy
Study: 36219388
Drug: Triple inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple inhaled therapy
Study: 33541356
Drug: Bronchodilators for
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators for monotherapy
Study: 33541436
Drug: Truncal ablation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truncal ablation, simultaneous iliac interrogation with intravascular ultrasound and stenting of significant (> 50%) iliac vein lesions plus compression therapy
Study: 33541436
Drug: Truncal ablation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truncal ablation and compression therapy
Study: 33542056
Drug: 40 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg·kg of rifampicin
Study: 33542056
Drug: 50 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg·kg of rifampicin
Study: 33542131
Drug: Responder-derived fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1 therapy
Study: 33542624
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI (budesonide/glycopyrrolate/formoterol fumarate) 320/18/9.6 µg
Study: 33542624
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI (glycopyrrolate/formoterol fumarate) 18/9.6 µg
Study: 33543056
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment after 14 weeks)
Study: 33544318
Drug: Vedolizumab 300-mg
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300-mg maintenance therapy every 8, 6, or 4 weeks
Study: 33544318
Drug: Vedolizumab 300-mg
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300-mg maintenance therapy every 8 weeks
Study: 33544318
Drug: Vedolizumab 300-mg
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300-mg maintenance therapy
Study: 33545083
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy (including primary induction) or colectomy during the COVID-19 pandemic period
Study: 33545083
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to rescue therapy during the COVID-19 pandemic period
Study: 33545083
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of rescue and primary induction therapies with biologicals, ciclosporin, or tofacitinib during the COVID-19 pandemic period
Study: 33545083
Drug: Ambulatory (outpatient)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory (outpatient) intravenous steroids during the COVID-19 pandemic period
Study: 33545083
Drug: Incidence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidence of SARS-CoV-2 during hospital treatment
Study: 33545389
Drug: ALK inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALK inhibitors (ALKi)
Study: 33545440
Drug: Therapeutic rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic rest using intramuscular morphine sulfate and promethazine
Study: 33546641
Drug: Brief individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief individual oral and visual information on vitamin D given by doctors at baseline and after four and ten months
Study: 33546731
Drug: Frailty score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frailty score pre-chemotherapy (T1) vs post-chemotherapy (T2)
Study: 33547528
Drug: P-PENK >
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-PENK > 84.8 pmol/mL at baseline
Study: 33547528
Drug: P-NGAL >
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-NGAL > 104 ng/mL at baseline
Study: 33547559
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus doses of morphine via patient-controlled analgesia
Study: 33547694
Drug: Equine-assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-assisted therapy (EAT)
Study: 33548397
Drug: Brodalumab (IL-17RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab (IL-17RA antagonist)
Study: 33548468
Drug: Reslizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab (3 mg/kg)
Study: 33548471
Drug: Inhaled triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triple therapy
Study: 33549128
Drug: ERITA (Emotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERITA (Emotion Regulation Individual Therapy for Adolescents) as an add-on to treatment as usual
Study: 33549447
Drug: Urinary potassium
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary potassium excretion in black individuals
Study: 33550173
Drug: Ticagrelor administration
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor administration
Study: 33550824
Drug: Furosemide, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide, dosage and duration not specified
Study: 33550846
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid testing (OFT) - supervised testing
Study: 33550846
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid testing (OFT) - unsupervised testing
Study: 38877777
Drug: Intravascular lithotripsy
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular lithotripsy (IVL) treatment
Study: 34941429
Drug: Transcranial Photobiomodulation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Photobiomodulation, details on dosage and duration not available
Study: 33551992
Drug: Lutetium 177-DOTATATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutetium 177-DOTATATE therapy
Study: 33553233
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of cinnamon added to oatmeal prepared with milk
Study: 33554038
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg intravenously every 3 weeks)
Study: 33554514
Drug: MR-proADM threshold
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-proADM threshold of 1.75 nmol/L
Study: 33555033
Drug: Ribociclib 400
Normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 400 mg single oral dose
Study: 33555033
Drug: Ribociclib 400
Normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 400 mg daily, 3 weeks on and 1 week off
Study: 33555265
Drug: START with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: START with mobile augmentation
Study: 33555436
Drug: In-hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital treatment for COVID-19 in patients < 65 years
Study: 33555436
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to ICU and treatment with IMV in patients < 65 years
Study: 33555777
Drug: Invasive mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive mechanical ventilation, vasoactive drugs, and new renal replacement therapy (n = 655)
Study: 33555777
Drug: Discharge home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discharge home (invasive mechanical ventilation, vasoactive drugs, and renal replacement)
Study: 33556493
Drug: Palliative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative care intervention (PC) including a single in-person outpatient palliative care consultation (OPCC) plus 6 weekly, PC nurse coach-led telehealth sessions.
Study: 33557591
Drug: hyperimmune anti-SARS-CoV-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma
Study: 33557844
Drug: 5-fluorouracile-based treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracile-based treatments (first- and second-line)
Study: 33557844
Drug: Treatment withdrawal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment withdrawal and cancer progression
Study: 33558125
Drug: Low-dose cone-beam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cone-beam CT angiography (5-second rotation, n=45)
Study: 33558294
Drug: Micafungin 8
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin 8 mg/kg daily for a mean of 13.3 days (±5.2 days)
Study: 33558294
Drug: Micafungin 8
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin 8 mg/kg daily
Study: 33558436
Drug: Subcutaneous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous belimumab 200 mg plus standard therapy
Study: 33558725
Drug: T cells
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cells engineered with a T cell receptor targeting HPV-16 E7
Study: 33559286
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment in DLBCL patients who are HBsAg positive
Study: 33559286
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment in DLBCL patients who are HBsAg negative
Study: 33559842
Drug: Twice-weekly 25-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly 25-mg prefilled liquid Yisaipu (group I)
Study: 33559842
Drug: Once-weekly 50-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly 50-mg prefilled liquid Yisaipu (group II)
Study: 33559842
Drug: Twice-weekly 25-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly 25-mg lyophilized Yisaipu (group III)
Study: 33560097
Drug: Micafungin 150
Normalized name: micafungin 150 MG in 150 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 150 mg loading dose followed by 100 mg daily
Study: 33560375
Drug: Multiagent initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent initial chemotherapy
Study: 33560375
Drug: Multiagent initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent initial chemotherapy with anthracycline and etoposide
Study: 33560394
Drug: IV copanlisib
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV copanlisib 60 mg on days 1, 8, and 15 of 28-day cycles for a median of 23 weeks
Study: 33560399
Drug: Omidubicel in
Normalized name: omidubicel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omidubicel in combination with unmanipulated UCB graft
Study: 33561011
Drug: Insulin deprivation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin deprivation for 5.4 ± 0.6 hours in T1D participants
Study: 33561011
Drug: Insulin deprivation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin deprivation in T1D participants
Study: 33561122
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol intake (additional 300 mg per day)
Study: 33562091
Drug: Rifamycin SV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifamycin SV, 600 mg modified release tablets, taken three times a day for 14 days (total daily intake: 1800 mg)
Study: 33563894
Drug: Panobinostat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (10 or 15 mg), lenalidomide 15 mg, bortezomib 1 mg/m²
Study: 33565026
Drug: Lasmiditan 100
Normalized name: lasmiditan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan 100 mg (Cohort 1)
Study: 33565026
Drug: Lasmiditan 200
Normalized name: lasmiditan 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan 200 mg (Cohort 2)
Study: 33566467
Drug: Urinary (tissue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary (tissue inhibitor of metalloproteinases-2) × (insulin-like growth factor binding protein 7) test
Study: 33567087
Drug: SARS-CoV-2-specific antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2-specific antibodies testing using VITROS Anti-SARS-CoV-2 IgG test
Study: 33567192
Drug: Unilateral vestibular
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral vestibular implant (prosthesis)
Study: 33567333
Drug: Ceftolozane/Tazobactam (C/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/Tazobactam (C/T) 3 g (ceftolozane 2 g/tazobactam 1 g) as a 60-minute intravenous infusion